Jefferies & Co Downgrades Osiris Therapeutics (OSIR) to Underperform
More News related to OSIR
- Osiris Therapeutics to Present at 20th Annual Piper Jaffray Health Care Conference
- Osiris Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
- Osiris Therapeutics Reports Third Quarter 2008 Financial Results
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Osiris Announces Third Quarter 2008 Financial Results Conference Call
More News related to Downgrades
- POZEN (POZN) Announces Positive Top Line Results for Its PN 400 Phase 3 Trials
- Pfizer (PFE) Announces Results of Lipitor Study
- Vical (VICL) Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
- Questcor Pharma (QCOR) Resubmits sNDA to FDA for H.P. Acthar(r) Gel
- MAKO Surgical Corp. (MAKO) Receives FDA Clearance to Market Both Its Version 2.0 Tactile Guidance System(tm) and Its Bicompartmental Knee Resurfacing Implant System
Jefferies & Co downgrades Osiris Therapeutics (Nasdaq: OSIR) from Hold to Underperform. Price target $11.
Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.
Related Categories
DowngradesStocks Mentioned
-0.49Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Osiris
D. Jeffrey Rice on Aug 3, 2008 10:58 AMI am pretty close to this company and see no justification for this downgrade. In fact as far as I can see Osiris has acomplished an amazing amount in the past year+. I might also remind investors that if the Graft vs Host indication recieves FDA approval and if the the Chron's indication is accepted many doctors will not wait for the FDA approval in the other indications.